Analyze Diet

Actions of PAF receptor antagonists in horses with the allergic skin disease sweet itch.

Abstract: Platelet activating factor (PAF) mimics the effects of Culicoides antigen by inducing oedema and inflammatory cell accumulation in the dermis of horses with the allergic skin disease, sweet itch. PAF could therefore contribute to antigen-induced inflammatory changes in these horses. We now report that intravenous administration of the PAF receptor antagonist WEB 2086 (3 mg kg-1), at a dose that inhibited the vascular and cellular responses to PAF in sweet itch horses, reduced Culicoides antigen-induced oedema at 1 h by 73% and at 8 h by 71% (p < 0.05). Neutrophil accumulation and eosinophil recruitment were not significantly reduced by WEB 2086 or a second hetrazepine PAF receptor antagonist WEB 2170 (0.1 mg kg-1). These findings suggest a key role for PAF in oedema formation, but not inflammatory cell accumulation, induced by Culicoides antigen in the skin of sweet itch horses.
Publication Date: 1995-10-01 PubMed ID: 8564516DOI: 10.1007/BF01757697Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The study reports on how platelet activating factor (PAF) contributes to the allergic skin disease sweet itch in horses. By using PAF receptor antagonists, the researchers could significantly reduce swelling caused by the disease, but found no significant change in the accumulation of inflammatory cells.

Research Goal and Rationale

  • The aim of this study was to investigate the role of platelet activating factor (PAF) in inducing inflammatory responses in horses that suffer from sweet itch, a common allergic skin disease caused by the Culicoides antigen. The researchers also aimed to establish if PAF receptor antagonists could be used to inhibit these responses and provide a possible therapeutic intervention.

Methodology

  • The researchers utilized PAF, which mimics the effects of the Culicoides antigen causing inflammation and swelling. They also employed the use of PAF receptor antagonists, specifically WEB 2086 and WEB 2170. These were administered intravenously to horses suffering from sweet itch.
  • A key process of the methodology was measuring the response of the horses to the PAF and the PAF receptor antagonists, observing both edema (swelling) and inflammatory cell accumulation.

Findings

  • Results demonstrated that administration of the PAF receptor antagonist WEB 2086 significantly reduced Culicoides antigen-induced swelling by approximately 73% at 1 hour and 71% at 8 hours. These results were statistically significant (p<0.05).
  • However, the neutrophil accumulation and eosinophil recruitment – both indicators of inflammation – were not significantly reduced by either WEB 2086 or the second antagonist, WEB 2170.

Conclusion

  • The study concluded that PAF plays a crucial role in inducing edema formation in horses suffering from sweet itch. However, the accumulation of inflammatory cells was not significantly affected by antagonists of the PAF receptor.
  • This suggests that while PAF receptor antagonists might aid in reducing swelling in horses with sweet itch, a comprehensive understanding of managing the inflammatory response requires further research.

Cite This Article

APA
Foster AP, Lees P, Cunningham FM. (1995). Actions of PAF receptor antagonists in horses with the allergic skin disease sweet itch. Inflamm Res, 44(10), 412-417. https://doi.org/10.1007/BF01757697

Publication

ISSN: 1023-3830
NlmUniqueID: 9508160
Country: Switzerland
Language: English
Volume: 44
Issue: 10
Pages: 412-417

Researcher Affiliations

Foster, A P
  • Department of Veterinary Basic Sciences, Royal Veterinary College, Hatfield, Hertfordshire, UK.
Lees, P
    Cunningham, F M

      MeSH Terms

      • Animals
      • Azepines / administration & dosage
      • Azepines / therapeutic use
      • Ceratopogonidae / immunology
      • Dermatitis, Allergic Contact / drug therapy
      • Dermatitis, Allergic Contact / immunology
      • Dermatitis, Allergic Contact / veterinary
      • Edema / drug therapy
      • Edema / immunology
      • Edema / veterinary
      • Female
      • Horse Diseases / drug therapy
      • Horse Diseases / immunology
      • Horses / physiology
      • Injections, Intradermal
      • Injections, Intravenous
      • Insect Bites and Stings / immunology
      • Insect Bites and Stings / veterinary
      • Male
      • Platelet Aggregation Inhibitors / administration & dosage
      • Platelet Aggregation Inhibitors / therapeutic use
      • Platelet Membrane Glycoproteins / antagonists & inhibitors
      • Pruritus / drug therapy
      • Pruritus / immunology
      • Pruritus / veterinary
      • Receptors, Cell Surface
      • Receptors, G-Protein-Coupled
      • Triazoles / administration & dosage
      • Triazoles / therapeutic use

      References

      This article includes 18 references
      1. Sanz MJ, Weg VB, Walsh DT, Williams TJ, Nourshargh S. Differential effects of the PAF receptor antagonist UK-74,505 on neutrophil and eosinophil accumulation in guinea-pig skin.. Br J Pharmacol 1994 Oct;113(2):513-21.
      2. Mellor PS, McCraig J. The probable cause of "sweet itch" in England.. Vet Rec 1974 Nov 2;95(18):411-5.
        pubmed: 4451336doi: 10.1136/vr.95.18.411google scholar: lookup
      3. Foster AP, Lees P, Cunningham FM. Platelet activating factor is a mediator of equine neutrophil and eosinophil migration in vitro.. Res Vet Sci 1992 Sep;53(2):223-9.
        pubmed: 1332153doi: 10.1016/0034-5288(92)90114-hgoogle scholar: lookup
      4. Matthews AG, Imlah P, McPherson EA. A reagin-like antibody in horse serum: 1. Occurrence and some biological properties.. Vet Res Commun 1983 Jan;6(1):13-23.
        pubmed: 6868343doi: 10.1007/BF02214891google scholar: lookup
      5. Weg VB, Watson ML, Cordeiro RS, Williams TJ. Histamine, leukotriene D4 and platelet-activating factor in guinea pig passive cutaneous anaphylaxis.. Eur J Pharmacol 1991 Nov 5;204(2):157-63.
        pubmed: 1687219doi: 10.1016/0014-2999(91)90700-zgoogle scholar: lookup
      6. Teixeira MM, Hellewell PG. Effect of a 5-lipoxygenase inhibitor, ZM 230487, on cutaneous allergic inflammation in the guinea-pig.. Br J Pharmacol 1994 Apr;111(4):1205-11.
      7. Foster AP, Lees P, Cunningham FM. Platelet activating factor mimics antigen-induced cutaneous inflammatory responses in sweet itch horses.. Vet Immunol Immunopathol 1995 Jan;44(2):115-28.
        pubmed: 7747395doi: 10.1016/0165-2427(94)05299-8google scholar: lookup
      8. Foster AP, Lees P, Andrews MJ, Cunningham FM. Effects of WEB 2086, an antagonist to the receptor for platelet-activating factor (PAF), on PAF-induced responses in the horse.. Equine Vet J 1992 May;24(3):203-7.
      9. Foster AP, Cunningham FM, Lees P. Inflammatory effects of platelet activating factor (PAF) in equine skin.. Equine Vet J 1992 May;24(3):208-14.
      10. Baker KP, Quinn PJ. A report on clinical aspects and histopathology of sweet itch.. Equine Vet J 1978 Oct;10(4):243-8.
      11. Huntley JF. Mast cells and basophils: a review of their heterogeneity and function.. J Comp Pathol 1992 Nov;107(4):349-72.
        pubmed: 1291584doi: 10.1016/0021-9975(92)90010-rgoogle scholar: lookup
      12. Weber KH, Heuer HO. Hetrazepines as antagonists of platelet activating factor.. Med Res Rev 1989 Apr-Jun;9(2):181-218.
        pubmed: 2654522doi: 10.1002/med.2610090204google scholar: lookup
      13. Markey AC, Barker JN, Archer CB, Guinot P, Lee TH, MacDonald DM. Platelet activating factor-induced clinical and histopathologic responses in atopic skin and their modification by the platelet activating factor antagonist BN52063.. J Am Acad Dermatol 1990 Aug;23(2 Pt 1):263-8.
        pubmed: 2212123doi: 10.1016/0190-9622(90)70210-9google scholar: lookup
      14. Hayes JP, Ridge SM, Griffith S, Barnes PJ, Chung KF. Inhibition of cutaneous and platelet responses to platelet-activating factor by oral WEB 2086 in man.. J Allergy Clin Immunol 1991 Jul;88(1):83-8.
        pubmed: 2071787doi: 10.1016/0091-6749(91)90304-7google scholar: lookup
      15. Chung KF, Dent G, McCusker M, Guinot P, Page CP, Barnes PJ. Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man.. Lancet 1987 Jan 31;1(8527):248-51.
        pubmed: 2880069doi: 10.1016/s0140-6736(87)90066-3google scholar: lookup
      16. Foster AP, Cunningham FM, Andrews MJ, Lees P. A comparison of the actions of platelet activating factor (PAF) antagonists WEB 2170 and WEB 2086 in the horse.. J Vet Pharmacol Ther 1993 Dec;16(4):477-87.
      17. Henocq E, Vargaftig BB. Skin eosinophilia in atopic patients.. J Allergy Clin Immunol 1988 Apr;81(4):691-5.
        pubmed: 3281998doi: 10.1016/0091-6749(88)91040-8google scholar: lookup
      18. Roberts NM, Page CP, Chung KF, Barnes PJ. Effect of a PAF antagonist, BN52063, on antigen-induced, acute, and late-onset cutaneous responses in atopic subjects.. J Allergy Clin Immunol 1988 Aug;82(2):236-41.
        pubmed: 3403863doi: 10.1016/0091-6749(88)91005-6google scholar: lookup

      Citations

      This article has been cited 0 times.